论文部分内容阅读
Background The incidence of heart failure after myocardial infarction is ever-growing,and it is urgent to develop improved treatments.An attractive approach is gene therapy;however,the clinical barrier has yet to be broken because of several issues,including the lack of an ideal vector supporting safe and long-term myocardial transgene expression.